Please use this identifier to cite or link to this item:
Full metadata record
DC FieldValueLanguage
dc.contributor.authorKumari, Sulekhaen
dc.contributor.authorThng, Steven Tien Guanen
dc.contributor.authorVerma, Navin Kumaren
dc.contributor.authorGautam, Hemant K.en
dc.identifier.citationKumari, S., Thng, S. T. G., Verma, N. K., & Gautam, H. K. (2018). Melanogenesis Inhibitors. Acta Dermato Venereologica, 98(10), 924-931. doi: 10.2340/00015555-3002en
dc.description.abstractAbnormally high production of melanin or melanogenesis in skin melanocytes results in hyperpigmentation disorders, such as melasma, senile lentigines or freckles. These hyperpigmentary skin disorders can significantly impact an individual’s appearance, and may cause emotional and psychological distress and reduced quality of life. A large number of melanogenesis inhibitors have been developed, but most have unwanted side-effects. Further research is needed to better understand the mechanisms of hyperpigmentary skin disorders and to develop potent and safe inhibitors of melanogenesis. This review summarizes the current understanding of melanogenesis regulatory pathways, the potential involvement of the immune system, various drugs in current use, and emerging treatment strategies to suppress melanogenesis.en
dc.format.extent8 p.en
dc.relation.ispartofseriesActa Dermato Venereologicaen
dc.rights© 2018 Acta Dermato-Venereologica. This is an open access article under the CC BY-NC license. Journal Compilationen
dc.subjectSkin Pigmentationen
dc.titleMelanogenesis Inhibitorsen
dc.typeJournal Articleen
dc.contributor.schoolLee Kong Chian School of Medicine (LKCMedicine)en
dc.description.versionPublished versionen
item.fulltextWith Fulltext-
Appears in Collections:LKCMedicine Journal Articles
Files in This Item:
File Description SizeFormat 
Melanogenesis Inhibitors.pdf1.3 MBAdobe PDFThumbnail

Google ScholarTM




Items in DR-NTU are protected by copyright, with all rights reserved, unless otherwise indicated.